APO Research
Talk to an analyst

APO RESEARCH · REPORT

Non-steroidal Anti-inflammatory Drugs (NSAID)

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Non-steroidal Anti-inflammatory Drugs (NSAID) Market Outlook and Growth Opportunities 2026

26 December 2025190 pages

Choose your research edition.

Industry ResearchNon-steroidal Anti-inflammatory Drugs (NSAID) Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Non-steroidal Anti-inflammatory Drugs (NSAID) Industry Growth and Trends Forecast to 203292 pages · $3,450 USDMarket StructureGlobal Non-steroidal Anti-inflammatory Drugs (NSAID) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032186 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Non-steroidal Anti-inflammatory Drugs (NSAID) Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Non-steroidal Anti-inflammatory Drugs (NSAID) Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Non-steroidal Anti-inflammatory Drugs (NSAID) market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Non-steroidal Anti-inflammatory Drugs (NSAID) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Non-steroidal Anti-inflammatory Drugs (NSAID) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Non-steroidal Anti-inflammatory Drugs (NSAID) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Non-steroidal Anti-inflammatory Drugs (NSAID) market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Non-steroidal Anti-inflammatory Drugs (NSAID) market include Merck Animal Health, Bayer, Zoetis, St. Joseph, Merial, Generic, Elanco, Ecotrin and Boehringer Ingelheim, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Non-steroidal Anti-inflammatory Drugs (NSAID) market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Non-steroidal Anti-inflammatory Drugs (NSAID) and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Non-steroidal Anti-inflammatory Drugs (NSAID) sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Non-steroidal Anti-inflammatory Drugs (NSAID) market size, projected growth trends, production technologies, key applications, and end-use industries.

Non-steroidal Anti-inflammatory Drugs (NSAID) Segment by Company

Merck Animal Health

Bayer

Zoetis

St. Joseph

Merial

Generic

Elanco

Ecotrin

Boehringer Ingelheim

Non-steroidal Anti-inflammatory Drugs (NSAID) Segment by Type

Propionic acid derivatives

Sulfonanilides

Anthranilic acid derivatives (Fenamates)

Salicylates

Enolic acid (Oxicam) derivatives

Selective COX-2 inhibitors (Coxibs)

Acetic acid derivatives

Non-steroidal Anti-inflammatory Drugs (NSAID) Segment by Application

Human

Animals

Others

Non-steroidal Anti-inflammatory Drugs (NSAID) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Non-steroidal Anti-inflammatory Drugs (NSAID) status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Non-steroidal Anti-inflammatory Drugs (NSAID) market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Non-steroidal Anti-inflammatory Drugs (NSAID) significant trends, drivers, influence factors in global and regions.

6. To analyze Non-steroidal Anti-inflammatory Drugs (NSAID) competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Non-steroidal Anti-inflammatory Drugs (NSAID) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Non-steroidal Anti-inflammatory Drugs (NSAID) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Non-steroidal Anti-inflammatory Drugs (NSAID).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Non-steroidal Anti-inflammatory Drugs (NSAID) market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Non-steroidal Anti-inflammatory Drugs (NSAID) industry.

Chapter 3: Detailed analysis of Non-steroidal Anti-inflammatory Drugs (NSAID) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Non-steroidal Anti-inflammatory Drugs (NSAID) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Non-steroidal Anti-inflammatory Drugs (NSAID) in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Non-steroidal Anti-inflammatory Drugs (NSAID) Industry Trends Table 2. Non-steroidal Anti-inflammatory Drugs (NSAID) Industry Drivers Table 3. Non-steroidal Anti-inflammatory Drugs (NSAID) Industry Opportunities and Challenges Table 4. Non-steroidal Anti-inflammatory Drugs (NSAID) Industry Restraints Table 5. Global Non-steroidal Anti-inflammatory Drugs (NSAID) Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Non-steroidal Anti-inflammatory Drugs (NSAID) Revenue Share by Company (2021-2026) Table 7. Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Volume by Company (W Units) & (2021-2026) Table 8. Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Volume Share by Company (2021-2026) Table 9. Global Non-steroidal Anti-inflammatory Drugs (NSAID) Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Non-steroidal Anti-inflammatory Drugs (NSAID) Company Ranking, (2024-2026) & (USD Million) Table 11. Global Non-steroidal Anti-inflammatory Drugs (NSAID) Key Company Manufacturing Base & Headquarters Table 12. Global Non-steroidal Anti-inflammatory Drugs (NSAID) Company, Product Type & Application Table 13. Global Non-steroidal Anti-inflammatory Drugs (NSAID) Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Non-steroidal Anti-inflammatory Drugs (NSAID) by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Propionic acid derivatives Table 18. Significant Companies of Sulfonanilides Table 19. Significant Companies of Anthranilic acid derivatives (Fenamates) Table 20. Significant Companies of Salicylates Table 21. Significant Companies of Enolic acid (Oxicam) derivatives Table 22. Significant Companies of Selective COX-2 inhibitors (Coxibs) Table 23. Significant Companies of Acetic acid derivatives Table 24. Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Volume by Type 2021 VS 2025 VS 2032 (W Units) Table 25. Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Volume by Type (2021-2026) & (W Units) Table 26. Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Volume by Type (2027-2032) & (W Units) Table 27. Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Volume Share by Type (2021-2026) Table 28. Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Volume Share by Type (2027-2032) Table 29. Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value by Type (2021-2026) & (US$ Million) Table 31. Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value by Type (2027-2032) & (US$ Million) Table 32. Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type (2021-2026) Table 33. Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type (2027-2032) Table 34. Significant Companies of Human Table 35. Significant Companies of Animals Table 36. Significant Companies of Others Table 37. Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Volume by Application 2021 VS 2025 VS 2032 (W Units) Table 38. Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Volume by Application (2021-2026) & (W Units) Table 39. Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Volume by Application (2027-2032) & (W Units) Table 40. Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Volume Share by Application (2021-2026) Table 41. Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Volume Share by Application (2027-2032) Table 42. Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 43. Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value by Application (2021-2026) & (US$ Million) Table 44. Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value by Application (2027-2032) & (US$ Million) Table 45. Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application (2021-2026) Table 46. Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application (2027-2032) Table 47. Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 48. Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales by Region (2021-2026) & (W Units) Table 49. Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Market Share by Region (2021-2026) Table 50. Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales by Region (2027-2032) & (W Units) Table 51. Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Market Share by Region (2027-2032) Table 52. Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 53. Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value by Region (2021-2026) & (US$ Million) Table 54. Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Region (2021-2026) Table 55. Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value by Region (2027-2032) & (US$ Million) Table 56. Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Region (2027-2032) Table 57. Global Non-steroidal Anti-inflammatory Drugs (NSAID) Market Average Price (US$/Unit) by Region (2021-2026) Table 58. Global Non-steroidal Anti-inflammatory Drugs (NSAID) Market Average Price (US$/Unit) by Region (2027-2032) Table 59. Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales by Country: 2021 VS 2025 VS 2032 (W Units) Table 60. Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales by Country (2021-2026) & (W Units) Table 62. Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Market Share by Country (2021-2026) Table 63. Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales by Country (2027-2032) & (W Units) Table 64. Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Market Share by Country (2027-2032) Table 65. Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value by Country (2021-2026) & (US$ Million) Table 66. Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Market Share by Country (2021-2026) Table 67. Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value by Country (2027-2032) & (US$ Million) Table 68. Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Market Share by Country (2027-2032) Table 69. Merck Animal Health Company Information Table 70. Merck Animal Health Business Overview Table 71. Merck Animal Health Non-steroidal Anti-inflammatory Drugs (NSAID) Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Merck Animal Health Non-steroidal Anti-inflammatory Drugs (NSAID) Product Portfolio Table 73. Merck Animal Health Recent Development Table 74. Bayer Company Information Table 75. Bayer Business Overview Table 76. Bayer Non-steroidal Anti-inflammatory Drugs (NSAID) Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Bayer Non-steroidal Anti-inflammatory Drugs (NSAID) Product Portfolio Table 78. Bayer Recent Development Table 79. Zoetis Company Information Table 80. Zoetis Business Overview Table 81. Zoetis Non-steroidal Anti-inflammatory Drugs (NSAID) Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Zoetis Non-steroidal Anti-inflammatory Drugs (NSAID) Product Portfolio Table 83. Zoetis Recent Development Table 84. St. Joseph Company Information Table 85. St. Joseph Business Overview Table 86. St. Joseph Non-steroidal Anti-inflammatory Drugs (NSAID) Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. St. Joseph Non-steroidal Anti-inflammatory Drugs (NSAID) Product Portfolio Table 88. St. Joseph Recent Development Table 89. Merial Company Information Table 90. Merial Business Overview Table 91. Merial Non-steroidal Anti-inflammatory Drugs (NSAID) Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Merial Non-steroidal Anti-inflammatory Drugs (NSAID) Product Portfolio Table 93. Merial Recent Development Table 94. Generic Company Information Table 95. Generic Business Overview Table 96. Generic Non-steroidal Anti-inflammatory Drugs (NSAID) Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Generic Non-steroidal Anti-inflammatory Drugs (NSAID) Product Portfolio Table 98. Generic Recent Development Table 99. Elanco Company Information Table 100. Elanco Business Overview Table 101. Elanco Non-steroidal Anti-inflammatory Drugs (NSAID) Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Elanco Non-steroidal Anti-inflammatory Drugs (NSAID) Product Portfolio Table 103. Elanco Recent Development Table 104. Ecotrin Company Information Table 105. Ecotrin Business Overview Table 106. Ecotrin Non-steroidal Anti-inflammatory Drugs (NSAID) Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Ecotrin Non-steroidal Anti-inflammatory Drugs (NSAID) Product Portfolio Table 108. Ecotrin Recent Development Table 109. Boehringer Ingelheim Company Information Table 110. Boehringer Ingelheim Business Overview Table 111. Boehringer Ingelheim Non-steroidal Anti-inflammatory Drugs (NSAID) Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Boehringer Ingelheim Non-steroidal Anti-inflammatory Drugs (NSAID) Product Portfolio Table 113. Boehringer Ingelheim Recent Development Table 114. Key Raw Materials Table 115. Raw Materials Key Suppliers Table 116. Non-steroidal Anti-inflammatory Drugs (NSAID) Distributors List Table 117. Non-steroidal Anti-inflammatory Drugs (NSAID) Customers List Table 118. Research Programs/Design for This Report Table 119. Authors List of This Report Table 120. Secondary Sources Table 121. Primary Sources List of Figures Figure 1. Non-steroidal Anti-inflammatory Drugs (NSAID) Product Image Figure 2. Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value (2021-2032) & (US$ Million) Figure 4. Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales (2021-2032) & (W Units) Figure 5. Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Non-steroidal Anti-inflammatory Drugs (NSAID) Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Propionic acid derivatives Image Figure 10. Sulfonanilides Image Figure 11. Anthranilic acid derivatives (Fenamates) Image Figure 12. Salicylates Image Figure 13. Enolic acid (Oxicam) derivatives Image Figure 14. Selective COX-2 inhibitors (Coxibs) Image Figure 15. Acetic acid derivatives Image Figure 16. Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Volume by Type (2021 VS 2025 VS 2032) & (W Units) Figure 17. Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Volume Share 2021 VS 2025 VS 2032 Figure 18. Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Volume Share by Type (2021-2032) Figure 19. Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share 2021 VS 2025 VS 2032 Figure 21. Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type (2021-2032) Figure 22. Human Image Figure 23. Animals Image Figure 24. Others Image Figure 25. Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Volume by Application (2021 VS 2025 VS 2032) & (W Units) Figure 26. Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Volume Share 2021 VS 2025 VS 2032 Figure 27. Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Volume Share by Application (2021-2032) Figure 28. Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 29. Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share 2021 VS 2025 VS 2032 Figure 30. Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application (2021-2032) Figure 31. Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales by Region: 2021 VS 2025 VS 2032 (W Units) Figure 32. Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 33. Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 34. Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 35. North America Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value (2021-2032) & (US$ Million) Figure 36. North America Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Europe Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value (2021-2032) & (US$ Million) Figure 38. Europe Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Asia-Pacific Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value (2021-2032) & (US$ Million) Figure 40. Asia-Pacific Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Country (%), 2025 VS 2032 Figure 41. South America Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value (2021-2032) & (US$ Million) Figure 42. South America Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Country (%), 2025 VS 2032 Figure 43. Middle East & Africa Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value (2021-2032) & (US$ Million) Figure 44. Middle East & Africa Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Country (%), 2025 VS 2032 Figure 45. USA Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. USA Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. USA Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Canada Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Canada Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Canada Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Mexico Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Mexico Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Mexico Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Germany Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Germany Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Germany Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. France Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. France Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. France Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. U.K. Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. U.K. Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. U.K. Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Italy Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Italy Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Italy Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Spain Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Spain Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Spain Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Russia Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Russia Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Russia Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Netherlands Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Netherlands Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Netherlands Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Nordic Countries Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Nordic Countries Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Nordic Countries Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. China Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. China Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. China Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Japan Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Japan Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Japan Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. South Korea Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. South Korea Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. South Korea Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. India Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. India Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. India Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Australia Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Australia Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Australia Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Southeast Asia Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Southeast Asia Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Southeast Asia Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Brazil Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Brazil Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Brazil Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Argentina Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Argentina Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Argentina Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Chile Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Chile Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Chile Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Colombia Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Colombia Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Colombia Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Peru Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Peru Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Peru Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Saudi Arabia Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Saudi Arabia Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Israel Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Israel Arabia Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Israel Arabia Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. UAE Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. UAE Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. UAE Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Turkey Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Turkey Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Turkey Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Iran Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Iran Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Iran Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Egypt Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 127. Egypt Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 128. Egypt Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 129. Non-steroidal Anti-inflammatory Drugs (NSAID) Value Chain Figure 130. Manufacturing Cost Structure Figure 131. Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Mode & Process Figure 132. Direct Comparison with Distribution Share Figure 133. Distributors Profiles Figure 134. Years Considered Figure 135. Research Process Figure 136. Key Executives Interviewed

Scope & coverage.

Types
  • Propionic acid derivatives
  • Sulfonanilides
  • Anthranilic acid derivatives (Fenamates)
  • Salicylates
  • Enolic acid (Oxicam) derivatives
  • Selective COX-2 inhibitors (Coxibs)
  • Acetic acid derivatives
Applications
  • Human
  • Animals
  • Others
Companies covered
  • Merck Animal Health
  • Bayer
  • Zoetis
  • St. Joseph
  • Merial
  • Generic
  • Elanco
  • Ecotrin
  • Boehringer Ingelheim

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value (2021-2032)
  4. 1.2.2 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Volume (2021-2032)
  5. 1.2.3 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Non-steroidal Anti-inflammatory Drugs (NSAID) Market Dynamics
  1. 2.1 Non-steroidal Anti-inflammatory Drugs (NSAID) Industry Trends
  2. 2.2 Non-steroidal Anti-inflammatory Drugs (NSAID) Industry Drivers
  3. 2.3 Non-steroidal Anti-inflammatory Drugs (NSAID) Industry Opportunities and Challenges
  4. 2.4 Non-steroidal Anti-inflammatory Drugs (NSAID) Industry Restraints
3 Non-steroidal Anti-inflammatory Drugs (NSAID) Market by Company
  1. 3.1 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Company Revenue Ranking in 2025
  2. 3.2 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Revenue by Company (2021-2026)
  3. 3.3 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Volume by Company (2021-2026)
  4. 3.4 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Average Price by Company (2021-2026)
  5. 3.5 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Company Ranking (2024-2026)
  6. 3.6 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Company Manufacturing Base and Headquarters
  7. 3.7 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Company Product Type and Application
  8. 3.8 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Non-steroidal Anti-inflammatory Drugs (NSAID) Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Non-steroidal Anti-inflammatory Drugs (NSAID) Market by Type
  1. 4.1 Non-steroidal Anti-inflammatory Drugs (NSAID) Type Introduction
  2. 4.1.1 Propionic acid derivatives
  3. 4.1.2 Sulfonanilides
  4. 4.1.3 Anthranilic acid derivatives (Fenamates)
  5. 4.1.4 Salicylates
  6. 4.1.5 Enolic acid (Oxicam) derivatives
  7. 4.1.6 Selective COX-2 inhibitors (Coxibs)
  8. 4.1.7 Acetic acid derivatives
  9. 4.2 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Volume by Type
  10. 4.2.1 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Volume by Type (2021 VS 2025 VS 2032)
  11. 4.2.2 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Volume by Type (2021-2032)
  12. 4.2.3 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Volume Share by Type (2021-2032)
  13. 4.3 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value by Type
  14. 4.3.1 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value by Type (2021 VS 2025 VS 2032)
  15. 4.3.2 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value by Type (2021-2032)
  16. 4.3.3 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type (2021-2032)
5 Non-steroidal Anti-inflammatory Drugs (NSAID) Market by Application
  1. 5.1 Non-steroidal Anti-inflammatory Drugs (NSAID) Application Introduction
  2. 5.1.1 Human
  3. 5.1.2 Animals
  4. 5.1.3 Others
  5. 5.2 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Volume by Application
  6. 5.2.1 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value by Application
  10. 5.3.1 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value by Application (2021-2032)
  12. 5.3.3 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application (2021-2032)
6 Non-steroidal Anti-inflammatory Drugs (NSAID) Regional Sales and Value Analysis
  1. 6.1 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales by Region (2021-2032)
  3. 6.2.1 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales by Region: 2021-2026
  4. 6.2.2 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales by Region (2027-2032)
  5. 6.3 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value by Region (2021-2032)
  7. 6.4.1 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value by Region: 2021-2026
  8. 6.4.2 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value by Region (2027-2032)
  9. 6.5 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value (2021-2032)
  12. 6.6.2 North America Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value (2021-2032)
  15. 6.7.2 Europe Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value (2021-2032)
  21. 6.9.2 South America Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Country, 2025 VS 2032
7 Non-steroidal Anti-inflammatory Drugs (NSAID) Country-level Sales and Value Analysis
  1. 7.1 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales by Country (2021-2032)
  4. 7.3.1 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales by Country (2021-2026)
  5. 7.3.2 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales by Country (2027-2032)
  6. 7.4 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value by Country (2021-2032)
  7. 7.4.1 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value by Country (2021-2026)
  8. 7.4.2 Global Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Merck Animal Health
  2. 8.1.1 Merck Animal Health Company Information
  3. 8.1.2 Merck Animal Health Business Overview
  4. 8.1.3 Merck Animal Health Non-steroidal Anti-inflammatory Drugs (NSAID) Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Merck Animal Health Non-steroidal Anti-inflammatory Drugs (NSAID) Product Portfolio
  6. 8.1.5 Merck Animal Health Recent Developments
  7. 8.2 Bayer
  8. 8.2.1 Bayer Company Information
  9. 8.2.2 Bayer Business Overview
  10. 8.2.3 Bayer Non-steroidal Anti-inflammatory Drugs (NSAID) Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Bayer Non-steroidal Anti-inflammatory Drugs (NSAID) Product Portfolio
  12. 8.2.5 Bayer Recent Developments
  13. 8.3 Zoetis
  14. 8.3.1 Zoetis Company Information
  15. 8.3.2 Zoetis Business Overview
  16. 8.3.3 Zoetis Non-steroidal Anti-inflammatory Drugs (NSAID) Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Zoetis Non-steroidal Anti-inflammatory Drugs (NSAID) Product Portfolio
  18. 8.3.5 Zoetis Recent Developments
  19. 8.4 St. Joseph
  20. 8.4.1 St. Joseph Company Information
  21. 8.4.2 St. Joseph Business Overview
  22. 8.4.3 St. Joseph Non-steroidal Anti-inflammatory Drugs (NSAID) Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 St. Joseph Non-steroidal Anti-inflammatory Drugs (NSAID) Product Portfolio
  24. 8.4.5 St. Joseph Recent Developments
  25. 8.5 Merial
  26. 8.5.1 Merial Company Information
  27. 8.5.2 Merial Business Overview
  28. 8.5.3 Merial Non-steroidal Anti-inflammatory Drugs (NSAID) Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Merial Non-steroidal Anti-inflammatory Drugs (NSAID) Product Portfolio
  30. 8.5.5 Merial Recent Developments
  31. 8.6 Generic
  32. 8.6.1 Generic Company Information
  33. 8.6.2 Generic Business Overview
  34. 8.6.3 Generic Non-steroidal Anti-inflammatory Drugs (NSAID) Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Generic Non-steroidal Anti-inflammatory Drugs (NSAID) Product Portfolio
  36. 8.6.5 Generic Recent Developments
  37. 8.7 Elanco
  38. 8.7.1 Elanco Company Information
  39. 8.7.2 Elanco Business Overview
  40. 8.7.3 Elanco Non-steroidal Anti-inflammatory Drugs (NSAID) Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Elanco Non-steroidal Anti-inflammatory Drugs (NSAID) Product Portfolio
  42. 8.7.5 Elanco Recent Developments
  43. 8.8 Ecotrin
  44. 8.8.1 Ecotrin Company Information
  45. 8.8.2 Ecotrin Business Overview
  46. 8.8.3 Ecotrin Non-steroidal Anti-inflammatory Drugs (NSAID) Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Ecotrin Non-steroidal Anti-inflammatory Drugs (NSAID) Product Portfolio
  48. 8.8.5 Ecotrin Recent Developments
  49. 8.9 Boehringer Ingelheim
  50. 8.9.1 Boehringer Ingelheim Company Information
  51. 8.9.2 Boehringer Ingelheim Business Overview
  52. 8.9.3 Boehringer Ingelheim Non-steroidal Anti-inflammatory Drugs (NSAID) Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Boehringer Ingelheim Non-steroidal Anti-inflammatory Drugs (NSAID) Product Portfolio
  54. 8.9.5 Boehringer Ingelheim Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Non-steroidal Anti-inflammatory Drugs (NSAID) Value Chain Analysis
  2. 9.1.1 Non-steroidal Anti-inflammatory Drugs (NSAID) Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Mode & Process
  6. 9.2 Non-steroidal Anti-inflammatory Drugs (NSAID) Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Non-steroidal Anti-inflammatory Drugs (NSAID) Distributors
  9. 9.2.3 Non-steroidal Anti-inflammatory Drugs (NSAID) Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst